Evidence map›Paper›PMID 32599906›Full record

ArticleCancers2020

Multiparametric Analysis of Longitudinal Quantitative MRI data to Identify Distinct Tumor Habitats in Preclinical Models of Breast Cancer.

Anum K Syed, Jennifer G Whisenant, Stephanie L Barnes, Anna G Sorace, Thomas E Yankeelov

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 51 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. MRI-based habitat imaging in cancer treatment: current technology, applications, and challenges.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Anum K SyedDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX 78712, USA.ORCID 0000-0002-4200-534X
Jennifer G WhisenantDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Stephanie L BarnesOden Institute for Computational Engineering and Sciences, The University of Texas at Austin, Austin, TX 78712, USA.
Anna G SoraceDepartment of Biomedical Engineering, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Thomas E YankeelovDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX 78712, USA.
The University of Texas at Austin · USLivestrong Foundation · USUniversity of Alabama at Birmingham · USVanderbilt University Medical Center · US

Funding

INTEGRATING OMICS AND QUANTITATIVE IMAGING DATA IN CO-CLINICAL TRIALS TO PREDICT TREATMENT RESPONSE IN TRIPLE NEGATIVE BREAST CANCERU24CA226110 · NCI · BAYLOR COLLEGE OF MEDICINE · PI LEWIS, MICHAEL T., RUBIN, DANIEL L · 2019 to 2023
$3.2M
Comprehensive Training Program in Imaging Science and InformaticsT32EB007507 · NIBIB · UNIVERSITY OF TEXAS AT AUSTIN · PI MARKEY, MIA K, RYLANDER, HENRY GRADY · 2009 to 2024
$2.7M
Evaluation and Validation of Imaging Biomarkers of Tumor Response to TreatmentR01CA138599 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MCINTYRE, JAMES OLIVER · 2010 to 2015
$2.2M
Personalizing immunotherapy in HER2+ breast cancer through quantitative imagingR01CA240589 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SORACE, ANNA C · 2020 to 2023
$1.6M
American Cancer Society RSG-18-006-01-CCECancer Prevention and Research Institute of Texas RR160005NCI NIH HHS 1U24 CA226110NCI NIH HHS R01CA138599NCI NIH HHS R01 CA240589NCI NIH HHS R01CA240589NCI NIH HHS U01CA17470NIBIB NIH HHS T32 EB007507NIBIB NIH HHS T32EB007507
6 · The paper itself

Abstract

This study identifies physiological tumor habitats from quantitative magnetic resonance imaging (MRI) data and evaluates their alterations in response to therapy. Two models of breast cancer (BT-474 and MDA-MB-231) were imaged longitudinally with diffusion-weighted MRI and dynamic contrast-enhanced MRI to quantify tumor cellularity and vascularity, respectively, during treatment with trastuzumab or albumin-bound paclitaxel. Tumors were stained for anti-CD31, anti-Ki-67, and H&E. Imaging and histology data were clustered to identify tumor habitats and percent tumor volume (MRI) or area (histology) of each habitat was quantified. Histological habitats were correlated with MRI habitats. Clustering of both the MRI and histology data yielded three clusters: high-vascularity high-cellularity (HV-HC), low-vascularity high-cellularity (LV-HC), and low-vascularity low-cellularity (LV-LC). At day 4, BT-474 tumors treated with trastuzumab showed a decrease in LV-HC (

Indexed as

diffusion-weighted MRIdynamic contrast-enhanced MRIhabitat imagingimmunohistochemistryintratumoral heterogeneity

Identifiers

PMID32599906
PMCPMC7352623
OpenAlexW3037383057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.